Abstract
The value of a pharmaceutical company may be defined as its pipeline or portfolio of products and their potential value in the marketplace. One strategy to help mitigate the multitude of risks in pharmaceutical product development is to balance a portfolio across therapeutic areas, levels of risk and potential for returns. Risks include unexpected toxicities, therapeutic failure and inappropriate risk-benefit for the patient, as well as technical, financial, regulatory, political or social failure. Strategic reviews of a company’s portfolio will help ensure its product line-up is balanced appropriately to meet corporate goals and that product risks have been considered.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
